FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:473-479 August 14, 1997 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Hepatic encephalopathy is a complex neuropsychiatric syndrome that may occur in such diverse clinical situations as inherited errors of the urea cycle, acute or chronic liver disease, and spontaneous or iatrogenic portosystemic venous shunting, including that following procedures to establish a transjugular intrahepatic portosystemic shunt. The clinical manifestations of this syndrome range from subtle abnormalities detectable only by psychometric testing to deep coma. Several grading systems have been proposed; one based on clinical and electroencephalographic abnormalities is shown in Table 1.¹ Hepatic encephalopathy may be present in 50 to 70 percent of all patients with cirrhosis, including those with . . . [Full Text of this Article]

Approach to Management

Reduction of Production and Absorption of Ammonia

Increased Metabolism of Ammonia in the Tissues

Reduction of False Neurotransmitters

Inhibition of -Aminobutyric Acid–Benzodiazepine Receptors

Correction of Manganese Deposition in the Basal Ganglia

Orthotopic Liver Transplantation

Source Information

From the Institute of Hepatology, University College London Medical School, 69–75 Chenies Mews, London WC1E 6HX, United Kingdom, where reprint requests should be addressed to Dr. Williams.

References

Related Letters:

Management of Hepatic Encephalopathy
Plauth M., Merli M., Kondrup J., Riordan S. M., Williams R.
Extract | Full Text  
N Engl J Med 1997; 337:1921-1922, Dec 25, 1997. Correspondence

This article has been cited by other articles:

• de Melo, R. T., Charneski, L., Hilas, O. (2008). Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm 65: 818-822 [Abstract] [Full Text]  
• Crone, C. C., Gabriel, G. M., DiMartini, A. (2006). An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist. Psychosomatics 47: 188-205 [Abstract] [Full Text]  
• Ford-Dunn, S (2005). Managing patients with cancer and advanced liver disease. Palliat Med 19: 563-565  
• Handlogten, M. E., Hong, S.-P., Zhang, L., Vander, A. W., Steinbaum, M. L., Campbell-Thompson, M., Weiner, I. D. (2005). Expression of the ammonia transporter proteins Rh B glycoprotein and Rh C glycoprotein in the intestinal tract. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1036-G1047 [Abstract] [Full Text]  
• DiMartini, A. F., Dew, M. A., Trzepacz, P. T. (2005). Organ Transplantation. Focus 3: 280-303 [Full Text]  
• Hawkes, N D, Thomas, G A O, Jurewicz, A, Williams, O M, Hillier, C E M, McQueen, I N F, Shortland, G (2001). Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad. Med. J. 77: 717-722 [Abstract] [Full Text]  
• Seymour, C. A, Whelan, K. (1999). Dietary management of hepatic encephalopathy. BMJ 318: 1364-1365 [Full Text]  
• Plauth, M., Merli, M., Kondrup, J., Riordan, S. M., Williams, R. (1997). Management of Hepatic Encephalopathy. NEJM 337: 1921-1922 [Full Text]